Physician profile
John Pender
NPI 1134113913
$2,379.84
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $361 · 2021: $266 · 2022: $127 · 2023: $19.89 · 2024: $17.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $377.49 | 2019-2021 | |
| Glaxosmithkline, LLC. | $325.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $324.19 | 2019-2022 | |
| Insmed, INC. | $178.04 | 2019 | |
| Intuitive Surgical, INC. | $145.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.55 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $100.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.80 | 2019-2020 | |
| Abbvie INC. | $61.87 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $56.09 | 2019-2020 | |
| Mylan Specialty L.P. | $55.12 | 2019-2021 | |
| Gilead Sciences, INC. | $53.82 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.51 | 2020-2021 | |
| Pfizer INC. | $51.18 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $48.71 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46.61 | 2019 | |
| Shire North American Group INC | $42.37 | 2019 | |
| Mallinckrodt Enterprises LLC | $36.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.71 | 2019 | |
| Paratek Pharmaceuticals, INC. | $28.06 | 2019 | |
| Shionogi INC | $22.76 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.15 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.96 | 2019 | |
| Allergan, INC. | $19.89 | 2019 | |
| United Therapeutics Corporation | $18.38 | 2021 | |
| Mayne Pharma Commercial LLC | $15.92 | 2020 | |
| Circassia INC. | $11.50 | 2019 | |
| Philips North America LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.